- Home
- UHT vs XNCR Comparison
UHT vs XNCR Comparison
Compare UHT & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UHT
- XNCR
- Stock Information
- Founded
- UHT 1986
- XNCR 1997
- Country
- UHT United States
- XNCR United States
- Employees
- UHT N/A
- XNCR N/A
- Industry
- UHT Real Estate Investment Trusts
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- UHT Real Estate
- XNCR Health Care
- Exchange
- UHT Nasdaq
- XNCR Nasdaq
- Market Cap
- UHT 575.4M
- XNCR 547.8M
- IPO Year
- UHT N/A
- XNCR 2013
- Fundamental
- Price
- UHT $41.56
- XNCR $9.25
- Analyst Decision
- UHT
- XNCR Buy
- Analyst Count
- UHT 0
- XNCR 10
- Target Price
- UHT N/A
- XNCR $20.22
- AVG Volume (30 Days)
- UHT 58.7K
- XNCR 762.5K
- Earning Date
- UHT 10-23-2025
- XNCR 11-05-2025
- Dividend Yield
- UHT 6.98%
- XNCR N/A
- EPS Growth
- UHT N/A
- XNCR N/A
- EPS
- UHT 1.30
- XNCR N/A
- Revenue
- UHT $99,952,000.00
- XNCR $146,929,000.00
- Revenue This Year
- UHT N/A
- XNCR $23.31
- Revenue Next Year
- UHT $0.81
- XNCR N/A
- P/E Ratio
- UHT $31.59
- XNCR N/A
- Revenue Growth
- UHT 0.31
- XNCR N/A
- 52 Week Low
- UHT $34.56
- XNCR $6.92
- 52 Week High
- UHT $47.30
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- UHT 57.30
- XNCR 67.02
- Support Level
- UHT $40.88
- XNCR $8.26
- Resistance Level
- UHT $42.08
- XNCR $8.73
- Average True Range (ATR)
- UHT 0.71
- XNCR 0.44
- MACD
- UHT 0.07
- XNCR 0.09
- Stochastic Oscillator
- UHT 64.10
- XNCR 85.03
About UHT Universal Health Realty Income Trust
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.